Griffin Securities Starts Ligand Pharma (LGND) at Buy; Recent Decline in Share Price Presents A Buying Opportunity
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $294.60 +2.00%
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Griffin Securities initiates coverage on Ligand Pharma (NASDAQ: LGND) with a Buy. PT $18.00.
Griffin analyst said, "Ligand’s investments are about to pay off handsomely: 1)Promacta sales are rising rapidly around the world and new indications are under development. The thrombocytopenia drug is gaining market share for ITP as the drug has entered new territories around the world and a new indication is likely – hepatitis C. 2) The Captisol platform opens new opportunities to partner with other drug companies at no risk. The modified cyclodextrin has passed regulatory muster and numerous compounds now in clinical trials use it to ensure proper bioavailability. 3) One drug may get an early approval. Onyx has submitted an NDA for carfilzomib for multiple myeloma based on Phase 2 data that has looked impressive."
For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.
Shares of Ligand Pharma closed at $10.59 yesterday.
Griffin analyst said, "Ligand’s investments are about to pay off handsomely: 1)Promacta sales are rising rapidly around the world and new indications are under development. The thrombocytopenia drug is gaining market share for ITP as the drug has entered new territories around the world and a new indication is likely – hepatitis C. 2) The Captisol platform opens new opportunities to partner with other drug companies at no risk. The modified cyclodextrin has passed regulatory muster and numerous compounds now in clinical trials use it to ensure proper bioavailability. 3) One drug may get an early approval. Onyx has submitted an NDA for carfilzomib for multiple myeloma based on Phase 2 data that has looked impressive."
For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.
Shares of Ligand Pharma closed at $10.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leerink Starts Ligand Pharma (LGND) at Outperform
- Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO
- Citi Starts Luxshare Precision (2475:HK) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
